{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:53:22Z","timestamp":1791291202715,"version":"4.3.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma is a B-cell malignancy characterized by the uncontrolled growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells express the receptor activator of nuclear factor \u03baB ligand (RANKL), induce RANKL expression in the bone marrow, and down-regulate expression of the decoy receptor osteoprotegerin, thereby promoting bone resorption. Targeting this system in myeloma has clear therapeutic potential. However, osteoprotegerin also binds tumor necrosis factor\u2013related apoptosis inducing ligand (TRAIL) and prevents TRAIL-induced apoptosis of myeloma cells. Whether or not osteoprotegerin can bind TRAIL and prevent apoptosis in vivo and the relative importance of osteoprotegerin binding to TRAIL and RANKL are unclear. In the present study, we have investigated the ability of an osteoprotegerin-like peptidomimetic (OP3-4), designed to block the RANKL\/RANK interaction, to inhibit osteoclastic bone resorption and TRAIL-induced apoptosis in vitro and myeloma bone disease in vivo. OP3-4 inhibited osteoclast formation (P &amp;lt; 0.01) and bone resorption (P &amp;lt; 0.01) in vitro. However, OP3-4 had no effect on TRAIL-induced apoptosis of RPMI 8226 myeloma cells. Treatment of 5T2MM myeloma\u2013bearing mice with OP3-4 decreased osteoclast number and the proportion of bone surface covered by osteoclasts (P &amp;lt; 0.05). Treatment also prevented the tumor-induced decrease in cancellous bone area and the development of osteolytic lesions (P &amp;lt; 0.05). OP3-4 also reduced tumor burden when compared with the control (P &amp;lt; 0.05). These data suggest that OP3-4 and the selective inhibition of RANKL, but not TRAIL activity, are effective in preventing myeloma bone disease and offer a novel therapeutic approach to treating this aspect of myeloma. [Cancer Res 2007;67(1):202\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-1287","type":"journal-article","created":{"date-parts":[[2007,1,8]],"date-time":"2007-01-08T17:33:21Z","timestamp":1168277601000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma"],"prefix":"10.1158","volume":"67","author":[{"given":"Deborah J.","family":"Heath","sequence":"first","affiliation":[{"name":"1Academic Unit of Bone Biology, Division of Clinical Sciences (South), University of Sheffield Medical School, Sheffield, Yorkshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[{"name":"2Department of Haematology and Immunology, Free University Brussels (VUB), Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[{"name":"3Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute for Cancer Research, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Gallagher","sequence":"additional","affiliation":[{"name":"1Academic Unit of Bone Biology, Division of Clinical Sciences (South), University of Sheffield Medical School, Sheffield, Yorkshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Prideaux","sequence":"additional","affiliation":[{"name":"1Academic Unit of Bone Biology, Division of Clinical Sciences (South), University of Sheffield Medical School, Sheffield, Yorkshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramachandran","family":"Murali","sequence":"additional","affiliation":[{"name":"3Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute for Cancer Research, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[{"name":"1Academic Unit of Bone Biology, Division of Clinical Sciences (South), University of Sheffield Medical School, Sheffield, Yorkshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,1,8]]},"reference":[{"key":"2022061622294101500_B1","doi-asserted-by":"crossref","unstructured":"Valentin-Opran A, Charhon S, Meunier P, Edouard C, Arlot M. Quantitative histology of myeloma-induced bone changes. Br J Haematol\u20081982; 52: 601\u201310.","DOI":"10.1111\/j.1365-2141.1982.tb03936.x"},{"key":"2022061622294101500_B2","doi-asserted-by":"crossref","unstructured":"Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest\u20081991; 88: 62\u20136.","DOI":"10.1172\/JCI115305"},{"key":"2022061622294101500_B3","doi-asserted-by":"crossref","unstructured":"Taube T, Beneton M, McCloskey E, Rogers S, Greaves M, Kanis J. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol\u20081992; 49: 192\u20138.","DOI":"10.1111\/j.1600-0609.1992.tb00046.x"},{"key":"2022061622294101500_B4","doi-asserted-by":"crossref","unstructured":"De Leenheer E, Mueller G, Vanderkerken V, Croucher P. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol\u20082004; 4: 340\u20136.","DOI":"10.1016\/j.coph.2004.03.011"},{"key":"2022061622294101500_B5","doi-asserted-by":"crossref","unstructured":"Nakagaw N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun\u20081998; 253: 395\u2013400.","DOI":"10.1006\/bbrc.1998.9788"},{"key":"2022061622294101500_B6","doi-asserted-by":"crossref","unstructured":"Kong Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature\u20081999; 397: 315\u201323.","DOI":"10.1038\/16852"},{"key":"2022061622294101500_B7","doi-asserted-by":"crossref","unstructured":"Simonet W, Lacey D, Dunstan C, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell\u20081997; 89: 309\u201319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"2022061622294101500_B8","doi-asserted-by":"crossref","unstructured":"Lacey D, Timms E, Tan H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell\u20081998; 93: 165\u201376.","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"2022061622294101500_B9","doi-asserted-by":"crossref","unstructured":"Yasuda D, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A\u20081998; 95: 3597\u2013602.","DOI":"10.1073\/pnas.95.7.3597"},{"key":"2022061622294101500_B10","doi-asserted-by":"crossref","unstructured":"Pearse R, Sordillo E, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumour progression. Proc Natl Acad Sci U S A\u20082001; 98: 11581\u20136.","DOI":"10.1073\/pnas.201394498"},{"key":"2022061622294101500_B11","doi-asserted-by":"crossref","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow microenvironment. Blood\u20082001; 98: 3527\u201333.","DOI":"10.1182\/blood.V98.13.3527"},{"key":"2022061622294101500_B12","doi-asserted-by":"crossref","unstructured":"Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-\u03baB) and RANKL expression in multiple myeloma. Br J Haematol\u20082002; 117: 86\u201392.","DOI":"10.1046\/j.1365-2141.2002.03417.x"},{"key":"2022061622294101500_B13","doi-asserted-by":"crossref","unstructured":"Sezer O, Heider U, Zavrski I, Kuhne A, Hofbauer L. RANK ligand and osteoprotegerin in myeloma bone disease. Blood\u20082003; 101: 2094\u20138.","DOI":"10.1182\/blood-2002-09-2684"},{"key":"2022061622294101500_B14","doi-asserted-by":"crossref","unstructured":"Sezer O, Heider U, Jakob C, Eucker J, Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Oncol\u20082002; 20: 353\u20134.","DOI":"10.1200\/JCO.2002.20.1.353"},{"key":"2022061622294101500_B15","doi-asserted-by":"crossref","unstructured":"Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood\u20082002; 99: 4646\u20137.","DOI":"10.1182\/blood-2002-01-0148"},{"key":"2022061622294101500_B16","unstructured":"Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor \u03ba-B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res\u20082003; 9: 1436\u201340."},{"key":"2022061622294101500_B17","doi-asserted-by":"crossref","unstructured":"Okada T, Akikusa S, Okuno H, Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis\u20082003; 220: 639\u201346.","DOI":"10.1023\/A:1027362507683"},{"key":"2022061622294101500_B18","doi-asserted-by":"crossref","unstructured":"Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood\u20082001; 98: 2269\u201371.","DOI":"10.1182\/blood.V98.7.2269"},{"key":"2022061622294101500_B19","doi-asserted-by":"crossref","unstructured":"Wittrant Y, Theoleyre C, Chipoy C, et al. RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta\u20082004; 1704: 49\u201357.","DOI":"10.1016\/j.bbcan.2004.05.002"},{"key":"2022061622294101500_B20","doi-asserted-by":"crossref","unstructured":"Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA\u20082004; 292: 490\u20135.","DOI":"10.1001\/jama.292.4.490"},{"key":"2022061622294101500_B21","doi-asserted-by":"crossref","unstructured":"Hofbauer L, Neubauer A, Heufelder A. Receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer\u20082001; 92: 460\u201370.","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D"},{"key":"2022061622294101500_B22","doi-asserted-by":"crossref","unstructured":"Croucher P, Shipman C, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood\u20082001; 98: 3534\u201340.","DOI":"10.1182\/blood.V98.13.3534"},{"key":"2022061622294101500_B23","unstructured":"Vanderkerken V, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumour burden and increases survival in a murine model of multiple myeloma. Cancer Res\u20082003; 63: 287\u20139."},{"key":"2022061622294101500_B24","doi-asserted-by":"crossref","unstructured":"Body J, Greipp P, Coleman R, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer\u20082003; 97: 887\u201392.","DOI":"10.1002\/cncr.11138"},{"key":"2022061622294101500_B25","doi-asserted-by":"crossref","unstructured":"Emery J, McDonnell P, Burke M, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem\u20081998; 273: 14363\u20137.","DOI":"10.1074\/jbc.273.23.14363"},{"key":"2022061622294101500_B26","unstructured":"Shipman C, Croucher P. Osteoprotegerin is a soluble decoy receptor for tumour necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res\u20082003; 63: 912\u20136."},{"key":"2022061622294101500_B27","doi-asserted-by":"crossref","unstructured":"Tinhofer I, Biedermann R, Krismer M, Cazzolara R, Greil R. A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J\u20082006; 20: 759\u201361.","DOI":"10.1096\/fj.05-4329fje"},{"key":"2022061622294101500_B28","unstructured":"Holen I, Croucher P, Hamdy F, Eaton C. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res\u20082002; 62: 1619\u201323."},{"key":"2022061622294101500_B29","doi-asserted-by":"crossref","unstructured":"Holen I, Shipman C. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond)\u20082006; 110: 279\u201391.","DOI":"10.1042\/CS20050175"},{"key":"2022061622294101500_B30","doi-asserted-by":"crossref","unstructured":"Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R. Disabling of receptor activator of nuclear factor-\u03baB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem\u20082004; 279: 8269\u201377.","DOI":"10.1074\/jbc.M309690200"},{"key":"2022061622294101500_B31","doi-asserted-by":"crossref","unstructured":"Barrett K, Willingham J, Garvin J, Willingham M. Advances in cytochemical methods for detection of apoptosis. J Histochem Cytochem\u20082001; 49: 821\u201332.","DOI":"10.1177\/002215540104900703"},{"key":"2022061622294101500_B32","doi-asserted-by":"crossref","unstructured":"Radl R, De Glopper E, Schuit H, Zurcher C. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice. J Immunol\u20081979; 122: 609\u201313.","DOI":"10.4049\/jimmunol.122.2.609"},{"key":"2022061622294101500_B33","unstructured":"Radl J, Croese J, Zurcher C, Vanden Enden-Vieveen M, De Leeuw M. Animal model of human disease: multiple myeloma. Am J Pathol\u20081988; 132: 177\u201381."},{"key":"2022061622294101500_B34","doi-asserted-by":"crossref","unstructured":"Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin like growth factor-1 acts as a chemoattractant for 5T2 multiple myeloma cells. Blood\u20081999; 93: 235\u201341.","DOI":"10.1182\/blood.V93.1.235"},{"key":"2022061622294101500_B35","doi-asserted-by":"crossref","unstructured":"Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33MM cells in the C57BL\/KaLwRij mouse. Br J Cancer\u20081997; 76: 451\u201360.","DOI":"10.1038\/bjc.1997.409"},{"key":"2022061622294101500_B36","doi-asserted-by":"crossref","unstructured":"Shipman C, Vanderkerken K, Rogers M, et al. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. B J Haematol\u20082000; 111: 283\u20136.","DOI":"10.1046\/j.1365-2141.2000.02310.x"},{"key":"2022061622294101500_B37","doi-asserted-by":"crossref","unstructured":"Banner D, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF\u03b2 complex: implications for TNF receptor activation. Cell\u20081993; 73: 431\u201345.","DOI":"10.1016\/0092-8674(93)90132-A"},{"key":"2022061622294101500_B38","doi-asserted-by":"crossref","unstructured":"Cha S, Sung B, Kim Y, et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem\u20082000; 275: 31171\u20137.","DOI":"10.1074\/jbc.M004414200"},{"key":"2022061622294101500_B39","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Pearse R, Johnson C, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol\u20082002; 116: 278\u201390.","DOI":"10.1046\/j.1365-2141.2002.03257.x"},{"key":"2022061622294101500_B40","doi-asserted-by":"crossref","unstructured":"Croucher PI, De Raeve H, Perry PJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res\u20082003; 18: 482\u201392.","DOI":"10.1359\/jbmr.2003.18.3.482"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/1\/202\/2567938\/202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/1\/202\/2567938\/202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T09:21:38Z","timestamp":1683710498000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/1\/202\/532945\/An-Osteoprotegerin-like-Peptidomimetic-Inhibits"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,8]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-1287","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}